What is the appropriate acute and definitive management for a 54‑year‑old woman with rheumatic mitral stenosis presenting with decompensated heart failure, atrial fibrillation with pulse deficit, severe dyspnea, peripheral edema, ascites, and hepatic congestion?

Management of Rheumatic Mitral Stenosis with Decompensated Heart Failure and Atrial Fibrillation

This patient requires immediate aggressive diuretic therapy, rate control with digoxin (with or without beta-blockers), anticoagulation with a vitamin K antagonist (warfarin) targeting INR 2.5-3.0, and urgent evaluation for percutaneous mitral balloon commissurotomy (PMBC) or surgical mitral valve replacement as definitive therapy. 1, 2, 3

Acute Management (First 24-48 Hours)

Hemodynamic Stabilization

• Intravenous loop diuretics (furosemide) are the cornerstone of acute therapy to relieve severe pulmonary and systemic congestion (dyspnea, rales, peripheral edema, ascites, hepatic congestion) 4
• Vasodilators (nitroprusside or nitroglycerin) can reduce preload and improve forward flow, but use cautiously given the already low blood pressure (100/65 mmHg) - only if systolic BP >100 mmHg 5
• Avoid aggressive afterload reduction in mitral stenosis as it may worsen hypotension without significantly improving cardiac output

Rate Control for Atrial Fibrillation

The pulse deficit (apical rate 100 bpm vs radial pulse 70 bpm) indicates poorly controlled atrial fibrillation with variable ventricular response:

• Digoxin is specifically recommended as first-line for rate control in mitral stenosis with heart failure 6, 2
• Beta-blockers (metoprolol, atenolol) can be added cautiously if hemodynamically tolerated, though the patient's borderline blood pressure and decompensated state warrant careful titration 7, 6
• Target heart rate: 60-80 bpm at rest, <110 bpm with activity 6

Anticoagulation - Critical and Non-Negotiable

Patients with rheumatic mitral stenosis and atrial fibrillation MUST receive vitamin K antagonist (warfarin) anticoagulation - NOACs are contraindicated in this specific population 1, 2, 3:

• Start warfarin immediately targeting INR 2.0-3.0 8, 2, 9
• Bridge with intravenous unfractionated heparin or subcutaneous low-molecular-weight heparin until INR therapeutic 9
• This is a Class I indication regardless of CHA₂DS₂-VASc score - rheumatic mitral stenosis is an absolute indication 1, 3

Critical pitfall: The 2020 ACC/AHA guidelines explicitly state that NOACs should NOT be used in rheumatic mitral stenosis - only warfarin 1, 3. This differs from non-valvular atrial fibrillation.

Diagnostic Workup (Within 24-48 Hours)

Transthoracic Echocardiography

Already likely performed, but confirm:

• Mitral valve area (severe stenosis = ≤1.0 cm²) 2, 10
• Mean transmitral gradient
• Pulmonary artery systolic pressure (likely >50 mmHg given clinical presentation)
• Left atrial size (likely severely enlarged)
• Valve morphology and calcification (Wilkins score for PMBC candidacy)
• Right ventricular function
• Tricuspid regurgitation severity

Transesophageal Echocardiography

Mandatory before any intervention to:

• Exclude left atrial/left atrial appendage thrombus (absolute contraindication to PMBC) 2, 11
• Better assess valve anatomy and suitability for PMBC
• Evaluate for mitral regurgitation severity

Critical consideration: Even with therapeutic INR, rheumatic mitral stenosis patients with atrial fibrillation have high rates of left atrial thrombus 11. TEE is non-negotiable before cardioversion or intervention.

Definitive Management Strategy

Patient Selection for PMBC vs Surgery

PMBC is indicated as first-line therapy if 2, 10:

• No left atrial thrombus on TEE
• Mitral regurgitation ≤ mild
• Favorable valve morphology:
  • Wilkins echocardiographic score ≤8
  • Minimal valve calcification on fluoroscopy
  • Pliable leaflets with commissural fusion
• No need for concomitant cardiac surgery

Surgical mitral valve replacement is indicated if 2, 10:

• Left atrial thrombus present (after 1-3 months anticoagulation if in appendage only)
• Moderate-to-severe mitral regurgitation
• Heavily calcified valve (Wilkins score >8)
• Failed prior PMBC
• Concomitant severe tricuspid regurgitation requiring repair

Timing of Intervention

Given this patient's Stage D disease (severe symptoms despite medical therapy, decompensated heart failure, hepatic congestion, ascites):

• Urgent intervention within days to weeks once hemodynamically stabilized 2
• Do NOT delay for prolonged medical optimization - the valve pathology is the primary problem
• Multidisciplinary Heart Team evaluation should occur within 48-72 hours 1, 3

Medical Therapy Optimization

Before Discharge (Post-Intervention)

• Continue warfarin indefinitely (INR 2.0-3.0) 2, 9
• Diuretics titrated to euvolemia (furosemide with or without spironolactone)
• Rate control with digoxin ± beta-blocker
• Consider ACE inhibitor/ARB only if residual LV dysfunction or heart failure symptoms persist post-intervention 12

Cardioversion Consideration

Do NOT attempt cardioversion before valve intervention 2:

• Sinus rhythm will not be maintained with severe mitral stenosis
• High risk of thromboembolism despite anticoagulation
• Consider cardioversion 2-4 weeks after successful PMBC or surgery if atrial fibrillation is recent-onset and left atrium not massively enlarged

Critical Pitfalls to Avoid

1. Using NOACs instead of warfarin - This is explicitly contraindicated in rheumatic mitral stenosis 1, 3

2. Delaying anticoagulation - Start immediately; the thromboembolic risk is extremely high with rheumatic MS + AF 9, 11

3. Attempting cardioversion without TEE - Even with therapeutic anticoagulation, left atrial thrombus rates are high 11

4. Over-diuresis - The patient has hepatic congestion and likely hypoalbuminemia; monitor for intravascular volume depletion despite peripheral edema 13

5. Aggressive vasodilator therapy - Limited benefit in fixed mitral stenosis and may cause hypotension

6. Delaying definitive intervention - Medical therapy alone cannot address the mechanical obstruction; this patient needs valve intervention urgently

7. Using digoxin alone for rate control during activity - Digoxin is only effective at rest; add beta-blocker for exercise rate control 7, 6

Prognosis and Follow-up

Post-PMBC or surgery, this patient should experience:

• Dramatic symptom improvement within weeks
• Resolution of hepatic congestion and ascites over 1-3 months
• Possible restoration of sinus rhythm if intervention performed early (though less likely given chronic AF)
• Long-term survival depends on successful intervention and maintenance of anticoagulation 14

The pulse deficit will resolve with adequate rate control, but the underlying atrial fibrillation will likely persist and requires lifelong anticoagulation.